These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258 [TBL] [Abstract][Full Text] [Related]
6. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. Zafeiriou Z; Jayaram A; Sharp A; de Bono JS Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496 [TBL] [Abstract][Full Text] [Related]
8. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? Mottet N; Clarke N; De Santis M; Zattoni F; Morote J; Joniau S BJU Int; 2015 Mar; 115(3):364-72. PubMed ID: 24628790 [TBL] [Abstract][Full Text] [Related]
9. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East. Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901 [TBL] [Abstract][Full Text] [Related]
10. How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer. Moul JW Can J Urol; 2019 Jun; 26(3):9782-9786. PubMed ID: 31180310 [TBL] [Abstract][Full Text] [Related]
11. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment]. Basset V; Flamand V; Crouzet S; Ploussard G Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738 [TBL] [Abstract][Full Text] [Related]
12. Management of castrate-resistant prostate cancer in older men. Ged Y; Horgan AM J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565 [TBL] [Abstract][Full Text] [Related]
13. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer]. Küronya Z; Bíró K; Gyergyay F; Géczi L Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885 [TBL] [Abstract][Full Text] [Related]
14. New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer. Genestreti G; Di Battista M; Cavallo G; Brandes AA Tumori; 2016 Aug; 102(4):361-6. PubMed ID: 27151879 [TBL] [Abstract][Full Text] [Related]
15. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival. Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428 [No Abstract] [Full Text] [Related]
16. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results. Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241 [TBL] [Abstract][Full Text] [Related]
17. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A; Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031 [TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628 [TBL] [Abstract][Full Text] [Related]
19. Current management of advanced and castration resistant prostate cancer. Gomella LG; Petrylak DP; Shayegan B Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717 [TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]